- Early trials of a vaccine that targets a specific gene found in tumors, known as KRAS, has proven to be effective in 84% of patients who had pancreatic or colorectal cancers recur after their initial treatment.
- Biotech company Orbis Health Solutions was approved to begin a phase 3 clinical trial of its melanoma vaccine.
- Results from a phase 2 trial found a drug-vaccine combination developed by Merck and Moderna cut the risk of recurrence or death in patients with severe melanomas by 49%.
- A breast cancer vaccine has shown promise in a phase 1 trial spearheaded by researchers at the Seattle-based University of Washington’s Cancer Vaccine Institute and is preparing to move to phase 2.
- A new vaccine, called SurVaxM, that fights the deadliest form of brain cancer, glioblastoma, has shown promise in early trials.
- A small, phase 1 study found promising results for a pancreatic cancer vaccine.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
